This ADC product is comprised of an anti-EGFR monoclonal antibody conjugated via a Mc-VC-PABC linker to MMAE. The MMAE is targeted to EGFR-positive cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the
* VAT and and shipping costs not included. Errors and price changes excepted